MD2 ECONOMIC CONSEQUENCES OF PROVIDING RITUXIMAB AS ATREATMENT ALTERNATIVE FOR RHEUMATOID ARTHRITIS IN THE NETHERLANDS
Nov 1, 2007, 00:00 AM
10.1016/S1098-3015(10)64897-8
https://www.valueinhealthjournal.com/article/S1098-3015(10)64897-8/fulltext
Section Title :
Section Order :
54
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)64897-8&doi=10.1016/S1098-3015(10)64897-8